ABN/ARSN

15 088 417 403

Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigma Pharmaceuticals Limited

1	ormation about buy-back  Type of buy-back	On-market buy-back			
2	Date Appendix 3C was given to ASX	13 September 2012			
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day  Before previous day   Previous day					
hav	e been received, before, and	, <b>1</b>	Previous day		
hav 3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	, <b>1</b>	Previous day		

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.5850
		Laurat			Lowest price paid: \$0.5600
		\$0.5650	price	paid:	Highest price allowed under rule 7.33: \$0.5964

## How many shares/units may still be bought back?

6	If the company/trust has disclosed	57,077,251
	an intention to buy back a maximum number of shares/units –	
	the remaining number of	
	shares/units to be bought back	

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 24 October 2013

== == == == ==

(Director/Company secretary)

Print name: SUE MORGAN